SCHEMBL10243922

SCHEMBL10243922

CCN(CCNC(=O)OC)C(C)c1ccnn1CC

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 3/20 0.35
NPC1 O15118 2/20 0.35
L3MBTL1 Q9Y468 1/20 0.34
MEN1 O00255 3/20 0.33
KMT2A Q03164 3/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
CTSK P43235 1/20 0.33
GAA P10253 1/20 0.33
HTT P42858 1/20 0.33
IDH1 O75874 1/20 0.32
ALDH1A1 P00352 2/20 0.32
HCRTR1 O43613 1/20 0.32
HCRTR2 O43614 1/20 0.32
MAPT P10636 1/20 0.32
HPGD P15428 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
MTNR1A P48039 2/20 0.31
MTNR1B P49286 2/20 0.31
PGR P06401 1/20 0.30
ADRA2A P08913 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10243567 0.87 TAS1R3 (0.34) L3MBTL1KMT2ACTSKGAAMTNR1A
SCHEMBL10244313 0.78 LMNA (0.35) RAB9ANPC1MEN1KMT2ASMN1; SMN2
SCHEMBL10244130 0.78 RAB9A (0.38) RAB9ANPC1L3MBTL1MEN1KMT2A
SCHEMBL10244695 0.77 SMN1; SMN2 (0.41) L3MBTL1SMN1; SMN2ALDH1A1MAPTNPSR1
SCHEMBL10243497 0.76 SLC22A1 (0.43) SMN1; SMN2ALDH1A1HPGDMTNR1AMTNR1B
SCHEMBL10243651 0.76 RAB9A (0.34) RAB9ANPC1L3MBTL1SMN1; SMN2HTT
SCHEMBL10243931 0.74 CYP2D6 (0.33) MEN1KMT2ASMN1; SMN2GAAALDH1A1
SCHEMBL10243634 0.73 TSHR (0.40) ALDH1A1HPGDMTNR1AMTNR1BPGR
SCHEMBL10244354 0.73 MTNR1B (0.32) RAB9AMEN1KMT2AALDH1A1MAPT
SCHEMBL10243156 0.73 ALDH1A1 (0.46) MEN1KMT2AALDH1A1MAPTNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281292-A1 10a-Azalide Compound IL17A, AZI2, HDAC9 RAB9A 5/4885NPC1 209/4885L3MBTL1 2853/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.